Non-Invasive Brain Stimulation 'Significantly' Improves Depression in Just 10 Days, Placebo-Controlled Trial Finds
核心洞察
A randomized clinical trial found once-daily intermittent theta-burst stimulation (搜索) (iTBS) significantly reduced clinician-rated depressive symptoms compared to sham after 10 days of treatment.
The study enrolled 73 adults with major depressive disorder (搜索), with the iTBS group showing greater improvement on clinician assessments, though self-reported symptoms showed little difference.
At four-week follow-up, the sham group caught up to the iTBS group, suggesting non-specific factors like expectancy and sensory influences may contribute to symptom improvement.
A new placebo-controlled clinical trial has demonstrated that intermittent theta-burst stimulation (搜索) (iTBS), a non-invasive form of transcranial magnetic stimulation, can significantly reduce clinician-rated depressive symptoms in adults with major depressive disorder (搜索) (MDD) after just 10 daily sessions. The findings, published in JAMA Network Open by researchers at UiT The Arctic University of Norway, provide rigorous evidence for a treatment already in clinical use while also raising intriguing questions about the role of placebo effects in brain stimulation research.
"Major depressive disorder (搜索) is the most common mental health issue in the world, affecting hundreds of millions of people at some point in their lives," the researchers note, underscoring the urgency of developing new treatment approaches for those who do not respond to existing therapies.
Study Design and Methodology
The randomized clinical trial enrolled 73 adults with MDD, aged between 22 and 65 years. Participants were divided into two groups: 41 received active iTBS treatment, while 32 underwent a sham procedure designed to mimic the experience without delivering therapeutic stimulation to the brain.
iTBS works by delivering focused magnetic fields through a coil pressed against the patient's head, activating neurons in the dorsolateral prefrontal cortex—a brain region linked to mood regulation and executive function. The sham condition was achieved using a modified coil with a reversed winding configuration and internal shielding, producing a diffuse and attenuated magnetic field insufficient for cortical stimulation while preserving comparable auditory and scalp sensations.
"In this randomized clinical trial of adults with MDD, a fixed 10-session schedule of once-daily iTBS resulted in greater reductions in clinician-rated depressive symptoms than sham during the treatment phase," the researchers write.
Key Findings and the Placebo Puzzle
After both 5 and 10 days of daily treatment, the iTBS group demonstrated notably better depression scores based on clinician-administered interviews compared to the placebo group. However, there was little difference between groups in self-reported symptom measures, a discrepancy that warrants further investigation.
Treatment was discontinued for all participants after 10 days. At the four-week follow-up, researchers observed an unexpected convergence: the iTBS group maintained their clinical improvement, while the sham group caught up, showing equivalent symptom reduction on average.
"The substantial symptom reduction in the sham group aligns with prior evidence that sham TMS is not physiologically inert but may involve non-specific factors such as expectancy-related, sensory, and contextual influences that contribute to symptom improvements," the researchers explain.
Clinical Implications
These findings carry important implications for both clinical practice and future research design. The short-term efficacy of iTBS supports its use as a rapid intervention, though the convergence of outcomes at follow-up suggests that treatment courses—which are often longer than the 10-day protocol studied here—may need to be optimized for sustained benefit.
"From a clinical perspective, these findings highlight the importance of treatment duration and follow-up when interpreting clinical response," the researchers state. "Treatment duration may shape outcomes, with fixed, short treatment courses potentially facilitating symptom improvement."
The study also underscores the need for carefully calibrated future trials, particularly regarding treatment duration, comparison with control groups, and the timing of final follow-up assessments. The robust placebo response observed suggests that the psychological impact of believing one is receiving treatment may itself contribute meaningfully to symptom reduction—a factor that must be accounted for in study design.